Iovance Biotherapeutics Reports Record Q3 Revenue of ~$122 Million, Narrowing Losses Below Estimates
Total Revenue Climbs ~80% Year-over-Year as Amtagvi Demand Accelerates and Gross Margin Reaches ~60% Related Stocks: IOVA ,
Total Revenue Climbs ~80% Year-over-Year as Amtagvi Demand Accelerates and Gross Margin Reaches ~60% Related Stocks: IOVA ,